Tim Franson, principal at Faegre Drinker Consulting, joins a panel of drug development regulatory experts to discuss the unprecedented and tumultuous nature of 2020, focusing on the simultaneous challenges of a once-in-a-century global pandemic, the resulting socioeconomic fallout, and political polarization regarding policy responses to the pandemic, civil rights protests and presidential elections, all of which may impact development and care processes. The Food and Drug Administration (FDA) has responded to these pressures with varying degrees of success and now faces an incoming administration that in many ways could not contrast more sharply with its predecessor.
Additional event speakers include:
- Frank Sasinowski, director at Hyman, Phelps & McNamara
- Steven Grossman, president of HPS Group
- David Fox, partner at Hogan Lovells
- Zan Fleming, M.D., executive chairman of Kinexum